CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026

Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components

Apr. 20, 2026 at 2:04am

Got story updates? Submit your updates here. ›

A highly abstract, geometric painting in muted earth tones, featuring sweeping arcs, concentric circles, and precise spirals, conveying the complex natural forces and structures underlying immune cell programming and gene delivery technologies.CREATE Medicines' innovative in vivo cell engineering platforms aim to unlock the full potential of the human immune system to treat complex diseases.Cambridge Today

CREATE Medicines, a clinical-stage biotechnology company pioneering in vivo immune cell programming, announced it will present new data on its multi-immune in vivo CAR portfolio and its all-RNA RetroT platform at the American Association for Cancer Research Annual Meeting 2026. The presentations will showcase simultaneous engineering of myeloid cells, NK cells, and T cells with tailored CAR mRNAs, as well as first-in-vivo evidence for RetroT demonstrating stable, durable CAR expression without viral components.

Why it matters

CREATE's presentations at AACR highlight the company's unique capability to rapidly iterate from clinical data to develop the next generation of in vivo cell therapies. The data showcases CREATE's progress in advancing the broadest portfolio of in vivo CAR therapies, supporting the largest human clinical dataset in the field, and validating the potential of its all-RNA RetroT platform as a path to stable, durable CAR expression without viral vectors.

The details

The data to be presented at AACR demonstrates simultaneous engineering of myeloid cells, NK cells, and T cells with tailored CAR mRNAs, driving tumor regression and remodeling of the tumor microenvironment in a colorectal cancer model. The first-in-vivo evidence for RetroT shows that CAR T cells engineered without double-strand breaks or viral vectors significantly reduced tumor burden in a leukemia model, validating the platform's potential as a path to stable, durable CAR expression.

  • The AACR Annual Meeting 2026 will take place from April 17–22, 2026 in San Diego.
  • The CREATE Medicines presentations will be held on Sunday, April 19, 2026 from 2–5 PM PT and Monday, April 20, 2026 from 9 AM–12 PM PT.

The players

CREATE Medicines, Inc.

A clinical-stage biotechnology company pioneering in vivo immune cell programming.

Robert Hofmeister, Ph.D.

The Chief Scientific Officer of CREATE Medicines.

Got photos? Submit your photos here. ›

What they’re saying

“CREATE was built to rapidly iterate directly from our clinical data and unlock the clear advantages of in vivo cell therapy.”

— Robert Hofmeister, Chief Scientific Officer of CREATE Medicines

What’s next

CREATE Medicines is advancing the broadest portfolio of in vivo CAR therapies, supporting the largest human clinical dataset in the field, and is positioned for near-term development of novel scalable therapies across autoimmune and oncology.

The takeaway

CREATE Medicines' presentations at AACR showcase the company's progress in developing innovative in vivo cell therapies, including its multi-immune CAR portfolio and the all-RNA RetroT platform, which have the potential to transform outcomes in autoimmunity and cancer.